Revium Recovery Inc. (RVRC): Thanks man, I had cleared out before 10a...

Thanks man, I had cleared out before 10am

DoubleJackie · 2020-11-25T14:05:16.7730000Z

Thanks man, I had cleared out before 10am yest. Made 40% plus recovered my losses. Actually it's going to pay for a week all inclusive in Aruba. Needed serious patience. Good luck

Play Episode

3min

Proactive - Interviews for investors

Quantum Base to list on AIM with £5M IPO plan

Quantum Base CEO Tom Taylor joined Stephen Gunnion in the Proactive studio with more about the company’s upcoming listing on the AIM market and its breakthrough anti-counterfeiting technology. Quantum Base, founded in 2013 as a spin-out from Lancaster University, has developed an atomic fingerprint that offers 100% secure authentication of goods, scannable with any smartphone. “It tells you 100% if something is real or it's fake,” Taylor said, describing the technology as a major leap in the fight against counterfeiting. Taylor explained that the technology has applications across sectors including brand protection, pharmaceuticals, tax stamps, banknotes, passports and even aerospace parts. The firm is already working with clients globally—from North America to the Middle East—and targeting both commercial brands and government organisations. The IPO is expected to raise £5 million, with £4.70 million already committed and trading set to begin on Friday under the ticker QUBE. The retail offer remains open. “We really want to grow… AIM really helps us grow,” Taylor said, noting the listing will support product development and expansion into new verticals. Key uses of the funds will include expanding Quantum Base’s commercial team and scaling its product reach into global markets. Looking ahead, Taylor said investors should watch for announcements of new customers and entry into new industries as milestones on the path to profitability. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications to stay updated. #QuantumBase #TomTaylor #AntiCounterfeiting #AtomicFingerprint #AIMListing #IPO2025 #SmartphoneSecurity #PharmaceuticalSecurity #BrandProtection #QuantumTech #QUBE #InvestmentNews #ProactiveInvestors

Proactive - Interviews for investors

Buru Energy secures strategic deal for LNG development

Buru Energy Ltd CEO Thomas Nador talked with Proactive about the company’s newly announced strategic development agreement with Clean Energy Fuels Australia Pty Ltd (CEFA) to co-develop the Rafael Gas Project. Nador explained that CEFA brings strong midstream and downstream capabilities, backed by I Squared Capital, which manages around $40 billion in assets. "They bring the right credentials, to look after the downstream and midstream elements of the project," he said. Buru, meanwhile, will focus on the upstream side of the Rafael development. The deal is described as a “watershed moment” for the company, as it provides a clear pathway toward developing a long-term gas and condensate business in northwest Western Australia—an area currently dependent on imported energy. Under the agreement, CEFA will fund, build, and operate a small-scale LNG facility on-site, with Buru paying a processing fee over the life of the project. This significantly reduces Buru’s capital exposure to only the upstream infrastructure—namely, two wells, one of which is already in place. A final investment decision is expected in late 2025 or early 2026, with first cash flows anticipated in the second half of 2027. According to Nador, the projected annual free cash flow from the Rafael development is expected to surpass the company’s current market capitalization. For more insights like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future updates. #BuruEnergy #RafaelGasProject #LNGDevelopment #AustralianEnergy #CleanEnergy #GasExploration #CEFA #ThomasNador #ProactiveInvestors #ASXEnergy #NaturalGas #EnergyInfrastructure #I2Capital #UpstreamEnergy #MidstreamDevelopment

Proactive - Interviews for investors

Titan Mining reports record 2024 production, expands resources

Titan Mining President Rita Adiani joined Steve Darling from Proactive to discuss the company’s year-end results, highlighting record production and strong financial performance in 2024. The company met the upper end of its production guidance, while costs were 10% lower than the low end of its all-in sustaining cost (AISC) guidance. In Q4 2024, Titan Mining produced 21.7 million pounds of payable zinc, marking a 56% increase compared to Q4 2023. Total full-year 2024 production reached 59.5 million pounds. The company also posted Q4 revenues of $26.3 million, representing a 318% increase from Q3 2024 and a 241% increase from Q4 2023. Adiani also shared updates on the company’s mineral resource expansion, noting that Titan completed an updated mineral resource estimate and extended the mine life for ESM’s zinc operations until 2033. The updated estimate reports a 22% increase in measured and indicated contained zinc pounds compared to the 2020 resource estimate. In addition to its zinc operations, Titan completed a maiden mineral resource estimate for the Kilbourne Graphite Project. The project now holds an open-pit constrained inferred mineral resource of 22 million U.S. short tons, with an average grade of 2.91% (Cg), containing 653,000 tons of graphite at a 1.50% cut-off grade. #proactiveinvestors #titanminingcorporation #tsx #ti #otcqb #timcf #TitanMining #ZincProduction #GraphiteMining #BatteryMetals #CriticalMinerals #MiningStocks #TSX #RitaAdiani #EVMaterials #GraphiteUSA #MiningExpansion #AgustaGroup #ProactiveInvestors

Proactive - Interviews for investors

OKYO Pharma achieves key stability milestone for Urcosimod in clinical development

OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share a significant advancement in the company’s ongoing drug development efforts. The company has successfully demonstrated that urcosimod—formerly known as OK-101—remains stable for more than two and a half years in single-use ampoules, which are used for patient administration. This milestone is a crucial step forward in ensuring the long-term viability of the drug as it progresses through clinical trials. Urcosimod is currently being evaluated in a Phase 2b clinical trial, which is a randomized, placebo-controlled, double-masked study involving 48 patients. The trial is focused on assessing the drug’s effectiveness in treating neurotrophic keratopathy (NCP), a serious and progressive degenerative eye disease. Jacob emphasized that achieving success in clinical development extends beyond obtaining positive clinical trial data. A crucial aspect of regulatory approval includes meeting the rigorous Chemistry, Manufacturing, and Controls (CMC) requirements set by the U.S. Food and Drug Administration (FDA). By demonstrating long-term stability, OKYO Pharma has strengthened its regulatory submission package, addressing an essential factor in the drug’s future approval and commercialization. The company recently completed Good Manufacturing Practice (GMP) stability assay testing of single-use ampoules containing urcosimod in an ophthalmic solution. The results were highly promising—ampoules stored under refrigerated conditions maintained stability for over two and a half years, while initial three-month data from samples stored at room temperature showed potency levels at or above 100%. These findings reinforce confidence in urcosimod’s shelf life and its potential for real-world clinical use. As OKYO Pharma continues to advance urcosimod through the regulatory and clinical development process, this stability milestone represents a critical achievement in its journey toward providing an effective tr

Followers	12
Posts	785
Boards Moderated	0
Alias Born	02/15/2018

Volume:	-
Day Range:
Bid:	0.5155
Ask:	1.49
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

RVRC Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free